<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26303">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764320</url>
  </required_header>
  <id_info>
    <org_study_id>16-001036</org_study_id>
    <secondary_id>PCORI</secondary_id>
    <nct_id>NCT02764320</nct_id>
  </id_info>
  <brief_title>The MOTS (Medication Overuse Treatment Strategy) Trial</brief_title>
  <acronym>MOTS</acronym>
  <official_title>Determining the Optimal Treatment Strategy for Patients Who Have Chronic Migraine With Medication Overuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are two commonly used treatment strategies for treating patients who have chronic
      migraine with medication overuse. This study will compare the outcomes amongst patients
      randomized to one of the two treatment strategies.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Moderate to Severe Headache Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary outcome measure is frequency of moderate to severe headache days (i.e. days on which a headache lasts for at least 2 hours and at any time peaks at moderate or severe intensity) during weeks 9-12 post-randomization. If non-inferiority is demonstrated for the primary outcome, then a test of superiority will be performed for the frequency of moderate to severe headache days during the first 2 weeks post-randomization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1280</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Discontinuation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate discontinuation of the overused medication(s) and migraine preventive therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preventive Therapy Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Migraine preventive therapy without immediate discontinuation of the overused medication(s)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment Strategy</intervention_name>
    <description>Both arms will initiate or optimize preventive medications. Subjects in the Discontinuation arm will stop overused medications and use an alternative rescue medication(s) with a limited frequency. Subjects in the Preventive Therapy Only arm will initiate or optimize preventive medications without immediately discontinuing the overused medication.</description>
    <arm_group_label>Discontinuation</arm_group_label>
    <arm_group_label>Preventive Therapy Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Adults, at least 21 years of age

          -  Chronic Migraine - diagnosed according to ICHD3beta criteria

          -  Medication Overuse - diagnosed according to ICHD3beta criteria

          -  Willingness to be randomized to either of the two treatment arms

          -  Willingness to maintain a headache diary

          -  Plan for follow-up care with the clinician

          -  No changes to migraine prophylactic therapy within the 4 weeks prior to
             randomization.

        Exclusion Criteria

          -  Younger than 21 years of age

          -  Headache diagnoses other than chronic migraine with medication overuse; episodic
             tension-type headache on 3 or fewer days per month is allowed

          -  Not willing to be randomized to either of the treatment arms

          -  Not willing to maintain a daily headache diary

          -  Not planning on follow-up care with the clinician

          -  In the opinion of the clinician, randomization to either treatment arm would be
             considered unsafe (ex: pregnancy, immediate discontinuation

          -  Prisoners

          -  Diminished decision-making capacity which in the investigator's opinion would
             interfere with the person's ability to provide informed consent and complete study
             procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd J Schwedt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David W Dodick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northern Arizona Healthcare Medical Group</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Neurological Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona Headache Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona Neurology Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Thunderbird</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Migraine and Headache Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida Headache Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham Women's Hospital Headache Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham Women's Hospital Neurology Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Headache Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DENT Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic General Neurology</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Headache Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>May 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Todd J. Schwedt</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
